Skip to content
MarketScale
‹ Back to IndustriesSciences

Will Ultraviolet Light Be Part of the New Cleaning Standard?

Justin Low, CEO of Finsen Light, discusses the limitations of traditional cleaning methods and how UV-C sterilization technology can help. This technology aims to mitigate issues of human error common with liquid cleaners. Finsen Light's innovation offers enhanced cleaning solutions crucial during the pandemic.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · Building ManagementCleaningCleaning PracticesDaniel Litwin Video
Share

Key takeaways

01

UV-C sterilization technology addresses gaps left by traditional cleaning methods.

02

Liquid cleaners are prone to human error, which the new technology can reduce.

03

Finsen Light focuses on improving hygiene practices during the pandemic.

Justin Low, CEO of Finsen Light, joined us to talk about his company and the challenges of conventional cleaning methods in the face of the pandemic.

According to Justin, liquid cleaners are prone to gaps of human error through repetition. Finsen light looks to bring UV-C sterilization technology to fill in those gaps for businesses everywhere in an affordable package. A long collaboration between medical researchers, electricians, and product designers has produced what Finsen Light believes will be a real gamechanger both in the COVID-19 era and for years to come.

UV-C light is a type of ultraviolet light that is capable of breaking up the DNA in germs and rendering them sterile and non-functional. It’s not a new technology, but it’s gaining a lot of traction due to its ability to kill airborne superbugs, such as SARS-CoV-2, the virus that causes COVID-19. One of the main challenges for Justin and his team was finding a way to make the technology accessible on a consumer level for businesses.

As to whether or not cleaning practices will ever return to pre-Coronavirus levels, Justin doesn’t think so. “Is this going to be the new normal for businesses in the future? I think the answer is ‘yes,’” said Justin.

At least there’s Finsen Light to light the way. 

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

JL
Justin Low

CEO

Finsen Light

Justin Low is the CEO of Finsen Light. He discussed the challenges of conventional cleaning methods and the role of UV-C sterilization technology in modern cleaning systems. His insights highlight potential improvements in addressing human errors in cleaning.